ArticleScientific reports2017
Infection with the Makona variant results in a delayed and distinct host immune response compared to previous Ebola virus variants.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 42 citations in OpenAlex.
- Delayed type I interferon response and the subsequent out-of-sequence cytokine signal inhibit T cell induction in non-surviving Ebola virus-infected patients.Frontiers in immunology · 2026Article
- Systems immunology of transcriptional responses to viral infection identifies conserved antiviral pathways across macaques and humans.Cell reports · 2024Article
- Hepatic and pulmonary macrophage activity in a mucosal challenge model of Ebola virus disease.Frontiers in immunology · 2024Article
- Machine learning-based analysis of Ebola virus' impact on gene expression in nonhuman primates.Frontiers in artificial intelligence · 2024Article
- Recent Advances in Therapeutic Approaches Against Ebola Virus Infection.Recent advances in anti-infective drug discovery · 2024Review
- Natural History of Nonhuman Primates After Oral Exposure to Ebola Virus Variant Makona.The Journal of infectious diseases · 2023Article
- Pathogenesis of Aerosolized Ebola Virus Variant Makona in Nonhuman Primates.The Journal of infectious diseases · 2023Article
- Ebola virus shed glycoprotein is toxic to human T, B, and natural killer lymphocytes.iScience · 2023Article
- Natural history of nonhuman primates after conjunctival exposure to Ebola virus.Scientific reports · 2023Article
- Extracellular vesicle storm during the course of Ebola virus infection in primates.Frontiers in cellular and infection microbiology · 2023Article
- Peripheral immune responses to filoviruses in a reservoir versus spillover hosts reveal transcriptional correlates of disease.Frontiers in immunology · 2023Article
- A Proteomic Approach to Study the Biological Role of Hepatitis C Virus Protein Core+1/ARFP.Viruses · 2022Article
- Macrophage infection, activation, and histopathological findings in ebolavirus infection.Frontiers in cellular and infection microbiology · 2022Review
- CD47 expression attenuates Ebola virus-induced immunopathology in mice.Antiviral research · 2022Article
- Article
- Distinct transcriptional responses to fatal Ebola virus infection in cynomolgus and rhesus macaques suggest species-specific immune responses.Emerging microbes & infections · 2021Article
- Interferon-Induced HERC5 Inhibits Ebola Virus Particle Production and Is Antagonized by Ebola Glycoprotein.Cells · 2021Article
- Article
- Ultrasensitive point-of-care immunoassay for secreted glycoprotein detects Ebola infection earlier than PCR.Science translational medicine · 2021Article
- Altered microRNA Transcriptome in Cultured Human Liver Cells upon Infection with Ebola Virus.International journal of molecular sciences · 2021Article
Corrections and comments
- Erratum issued
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
Zaire Ebolavirus (ZEBOV) continues to pose a significant threat to human health as highlighted by the recent epidemic that originated in West Africa and the ongoing outbreak in the Democratic Republic of the Congo. Although the ZEBOV variant responsible for this epidemic (Makona) shares significant genetic similarity with previously identified variants (Kikwit and Mayinga), recent reports suggest slower disease progression in nonhuman primates. However, the pathogenesis caused by the new variant is not fully understood. We present the first comprehensive approach in understanding ZEBOV-Makona pathogenesis in cynomolgus macaques by measuring changes in immune cell frequencies, plasma levels of immune mediators, and differentially expressed genes (DEGs) within whole blood (WB) and peripheral blood mononuclear cells (PBMC). Our combined approach revealed a link between: 1) increased interferon-stimulated gene expression, IFNα levels, and activated plasmacytoid dendritic cells; 2) higher proinflammatory gene expression, cytokine and chemokine levels, and non-classical monocytes; 3) gene signature of leukocyte activation and increased granulocytes; and 4) decreased expression of lymphocyte related genes and lymphopenia. In addition, our data strongly indicate delayed disease progression as well as limited overlap (~30%) in host transcriptome changes following ZEBOV-Makona infection compared to ZEBOV-Kikwit. These observations provide novel insight into the molecular mechanisms of ZEBOV-Makona pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.